Prediction and impact of attacks of Raynaud's phenomenon, as judged by XXXX perception.

@entity1 @entity6391
OBJECTIVE: To evaluate whether @entity1 can predict attacks of @entity6391 (if so, this would have implications for developing new treatments) and to evaluate the impact of @entity6391 attacks on quality of life (QoL). METHODS: Individuals with @entity6391 were invited through international @entity1 associations to participate in an online survey. RESULTS: Responses from 443 subjects with self-reported @entity6391 from 15 countries were evaluable. The mean age of subjects was 41 years (91% female). Fifty-eight per cent of subjects reported they could predict at least 51% of @entity6391 attacks, and 57% could predict attack severity either fairly well or better [with 43% predicting severity only poorly (30%) or very poorly (13%)]. Sixty-four per cent of subjects reported a poor or very poor current ability to prevent/control @entity6391 attacks. One hundred and eighty-two subjects (41%) reported current or previous use of medications for @entity6391 : 82% reported at least one currently used medication being tolerated, but only 16% reported at least one current medication being effective. Most subjects (78%) reported making at least one life adjustment due to @entity6391 , with more in subjects with secondary @entity6391 compared with primary @entity6391 (87% vs 71%, P = 0.001). Current QoL with @entity6391 was impaired [mean = 6/10 (10 best imaginable)] and secondary @entity6391 subjects reported a greater absolute improvement when asked to imagine their QoL without @entity6391 (2.3 vs 3.3 P = 0.0002). CONCLUSION: Subjects' ability to predict @entity6391 attacks is limited. Treatments were generally considered tolerable but seldom fully effective. Our results confirm an unmet need for new treatments. @entity6391 significantly impacts on QoL in all subjects.
